Dec 21, 2025 • Stock Traders Daily
SOMEWHAT-BEARISH
(HIMS) Risk Channels and Responsive Allocation
This article provides a stock analysis for Hims & Hers Health Inc. Class A (NASDAQ: HIMS), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The analysis reports elevated downside risk due to a lack of additional long-term support signals.
Dec 09, 2025 • Stock Traders Daily
BULLISH
(HIMS) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting strong sentiment across all time horizons supporting an overweight bias. It presents specific AI-generated trading strategies for HIMS, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis also points to an exceptional 112.6:1 risk-reward setup.
Dec 06, 2025 • The National Law Review
BEARISH
HIMS CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)
Kessler Topaz Meltzer & Check, LLP announced that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges that Hims & Hers made materially false or misleading statements and failed to disclose that it was deceptively promoting illegitimate versions of Wegovy, which put patient safety at risk and jeopardized its collaboration with Novo Nordisk. Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to contact the firm by August 25, 2025, to discuss potentially being appointed as a lead plaintiff.
Nov 18, 2025 • Investing.com
SOMEWHAT-BULLISH
Boughton, Hims & Hers health CLO, sells $112k in shares
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 2,637 shares valued at $112,151 on November 10, 2025. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed a quarter where Hims & Hers exceeded analyst expectations in revenue, EBITDA, and EPS, despite narrowing its 2025 revenue guidance.
Nov 17, 2025 • Seeking Alpha
BULLISH
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE)
Hims & Hers Health (HIMS) has announced a new share repurchase program of up to $250 million for its outstanding Class A common stock, to be executed over the next three years. This news follows the completion of its previous $100 million buyback program and led to a pre-market stock increase of 2.76% to $38.00.
Nov 17, 2025 • Investing.com
BULLISH
Hims & Hers Health board approves $250 million share repurchase program
Hims & Hers Health (NYSE:HIMS) announced its board has approved a new $250 million share repurchase program for its Class A common stock, set to expire in November 2028. This follows the complete utilization of a previous $100 million repurchase program. The company will repurchase shares through various methods, and the program can be suspended or discontinued at any time.